Dexcom (DXCM) Equity Average (2011 - 2026)

Dexcom (DXCM) has 16 years of Equity Average data on file, last reported at $2.9 billion in Q1 2026.

• Quarterly Equity Average rose 30.53% year-over-year to $2.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 billion (up 30.53% YoY) and the FY2025 annual result came in at $2.4 billion, up 16.24% from the prior year.
• Equity Average advanced to $2.9 billion in Q1 2026 per DXCM's latest filing, from $2.7 billion in the prior quarter.
• Across five years, Equity Average topped out at $2.9 billion in Q1 2026 and bottomed at $2.0 billion in Q4 2022.
• The 5-year median for Equity Average is $2.2 billion (2023), against an average of $2.3 billion.
• The widest annual swing landed in 2024, when Equity Average dropped 5.88%; it then surged 34.07% in 2025.
• Tracing DXCM's Equity Average over 5 years: stood at $2.0 billion in 2022, then increased by 9.61% to $2.2 billion in 2023, then retreated by 5.88% to $2.0 billion in 2024, then soared by 34.07% to $2.7 billion in 2025, then grew by 4.22% to $2.9 billion in 2026.
• Per Business Quant, the three latest DXCM Equity Average figures stand at $2.9 billion (Q1 2026), $2.7 billion (Q4 2025), and $2.6 billion (Q3 2025).

Peer Comparison